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Abstract
Renal replacement therapy in the form of renal transplantation (RT) is the treatment of 
choice in these patients. Various factors influence the graft survival, infections being most 
common. Infections account for 16% of patient deaths and 7.7% of death censored graft 
failure in renal transplant patients. Urinary tract infection (UTI) is the most common 
infectious complication accounting for 45–72% of all infections. According to few studies 
UTI may have a negative impact over the long term survival of renal allograft. There are 
multiple factors that predispose these patients to UTI. Elderly age group, female gender, 
increased duration of catheterization and anatomical abnormalities of the urinary tract 
are most common predisposing factors. E. coli is the most frequently isolated organ-
isms from the urine of these patients. We would proceed further with two cases which 
presented as UTI in post-transplant period. The first patient transplanted (living donor 
related) for diabetes induced end stage renal disease had developed UTI 4 years post-
transplant. The other patient underwent deceased donor renal transplant for adult poly-
cystic disease related chronic kidney disease, presented 2 years post-transplant with UTI.
Keywords: renal transplantation, urinary tract infection, renal allograft, graft function, 
immunosuppression
1. Introduction
Clinical information (Case 1): A 53-year-old male patient, with a history of arterial hyperten-
sion, type 2 diabetes mellitus, and renal failure, caused by diabetic nephropathy diagnosed 
5 years back and was on maintenance hemodialysis. The patient underwent live donor renal 
transplantation in June 2013. The intraoperative and post-operative period was unremarkable 
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and he was put on Tacrolimus based immunosuppression thereafter consisting of Prednisone 
(20 mg/day), Mycophenolate sodium (360 mg/day), and Tacrolimus (1.5 mg/day level:4.6 ng/
ml). He was on regular follow-up for routine urine examination, serum creatinine and serum 
electrolytes and hemogram. Nearly 4 years post-transplant he was admitted with complaints 
of low grade intermittent febrile episodes and painful micturition. There was slight rise in 
the serum creatinine levels to 2.4 mg/dL (baseline: 1.8 mg/dL). The urine output was how-
ever normal. Complete blood count performed revealed neutrophilic leukocytosis with total 
count of 14.2 × 10 6/μl, with predominance of neutrophils on differential, the absolute neu-
trophil count of 14 × 10 6/μl. Urine examination revealed urine albumin of +1 by dipstick 
method, pH of 5.0 and specific gravity of 1.020. Clinical information (Case 2): A 38-year-old 
female patient, underwent deceased donor renal transplantation for adult polycystic kidney 
disease induced chronic kidney disease. The intraoperative and post-operative period was 
unremarkable and she was on conventional Tacrolimus based immunosuppression thereafter 
consisting of Prednisone (20 mg/day), Mycophenolate sodium (360 mg/day), and Tacrolimus 
(1.5 mg/day; level:6.8 ng/dL). She was on regular monitoring for routine urine examination, 
renal function tests and complete blood counts. Nearly 2 years post-transplant she was admit-
ted with complaints of intermittent high grade febrile episodes, pain in abdomen and nausea. 
The serum creatinine level at the time of presentation was found to be raised to 3.6 mg/dL 
(baseline: 1.2 mg/dL). The patient had normal urine output. Complete blood count performed 
revealed neutrophilic leukocytosis with total count of 18.6 × 106/μl, with predominance of 
neutrophils on differential, the absolute neutrophil count of 12 × 106/μl. Urine examination 
revealed urine albumin of +2 by dipstick method, pH of 4.6 and specific gravity of 1.040. 
Summary: So here we have two patients who underwent renal transplant for end stage renal 
disease and presented with signs and symptoms of urinary tract infection. Both the patients 
presented with rise in serum creatinine as well as pyuria on urine examination(not written in 
the text above)clinical suspicion of urinary tract infection. We would in further sections study 
how we proceeded with both the cases, investigations performed and management of both. In 
this brief review we would discuss the incidence of urinary tract infection in post-transplant 
patients, risk factors and how to manage a case with UTI.
1.1. Incidence of posttransplant urinary tract infections
Transplantation has become the gold standard treatment of end-stage disease in the present era. Of 
all the organs that are transplanted, kidneys remain the most frequently transplanted organ [1–5]. 
RT is regarded as an effective treatment for patients with advanced chronic renal disease [1, 2]. 
Over the years various studies have been carried out globally to understand the factors that 
influence the graft function [1]. Multiple factors including technical expertise, donor-recipients 
related demographics, immunosuppressive regimens, infections, comorbid conditions have been 
implicated to influence the graft survival [1–3]. Infections are a common cause of morbidity and 
mortality after transplantation and it is widely known that RT patients have poor resistance to 
infection [4, 5]. Infections have been ranked second, as a cause of death in RT patients. According 
to the U.S. Renal Data System, the rate of first infection in the initial 3 years after kidney trans-
plantation is reported to be 45.0 per 100 patient-years of follow-up. It has been postulated that in 
immunocompromised RT recipients, UTI is the most common infection that affects the graft func-
tion and is held responsible for longer hospital stay and increased health care cost [3, 6, 7]. Becerra 
et al. stated that the length of stay in patients who develop UTI is 74 and 76% higher in men and 
women renal transplant recipients respectively, when compared to those without UTI [8].
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1.2. Burden of the disease
UTI is the most common type of hospital-acquired infection, accounting for nearly 40–50% of 
all infectious complications among RT patients followed by viral infections, pneumonia and 
surgical site infections [8, 9]. As per the data from Spanish Network for the Study of Infections 
in Transplantation (RESITRA) the incidence of cystitis per 100 recipient-years was 13.84 for 
renal, 3.09 for liver, 2.41 for heart and 1.36 for lung transplant recipients [10]. The incidence 
of pyelonephritis per 100 recipient-years was 3.66 for renal, 0.8 for liver, 0.3 for heart and 
0.6 for lung transplant recipients. UTI-associated bacteremia was seen in 39% of renal, 3% of 
liver, 3% of heart and none of the lung transplant recipients [11, 12]. The prevalence of UTI in 
RT patients ranges from 13 to 80% according to various studies [1, 2, 6, 13–16]. Few authors 
have also reported an incidence as low as 4% to as high as 75% [17–20]. The vast difference 
could however be attributed largely due to lack of uniform diagnostic criteria to define UTI, 
implementation of prophylactic regimen and ill-defined period of follow-up. The incidence of 
UTI in the early post-transplant period (first 6 months) is higher as compared to late periods. 
However it is this early occurrence of UTI that has a profound effect over the allograft survival. 
Nearly 84% of symptomatic UTI cases are recorded in the first 6 months after transplant [21].
Recurrent UTI is also one of the major cause that poses threat to renal allograft and 
the prevalence ranges from 2.9 to 27% in renal transplant recipients. Mohammad et al. 
reported an incidence of recurrent UTI in nearly 51.7% patients who underwent renal 
transplantation [22].
1.3. Definition and diagnostic criteria for UTI
A urinary tract infection is an infection causing signs and symptoms of cystitis or pyelone-
phritis (including the presence of signs of systemic inflammation), which is documented to be 
caused by an infectious agent. The diagnostic criteria for UTI are similar to those that are used 
for general population, however all symptomatic UTI are considered as complicated UTI in 
RT patients [23–25].
Pain and tenderness over the renal allograft or costovertebral region indicates symptomatic 
infection of the upper urinary tract.
Asymptomatic bacteriuria in women is defined as two consecutive clean-catch voided urine 
specimens >24 hours apart with isolation of the same organism in quantitative counts of 
≥105 CFU/mL. However in males a single clean catch urine specimen with isolation of single 
organism in quantitative counts of ≥105 CFU/mL is regarded as asymptomatic bacteriuria. 
In case of urethral catheterization bacteriuria is defined as isolation of a single organism in 
quantitative counts of ≥102 CFU/mL in a single specimen.
2. Risk factors associated with development of UTI in renal 
transplant recipients
Post-transplant UTI in renal allograft recipients is of multifactorial origin and is determined 
by interaction between host factors, abnormalities associated with the anatomy of the uri-
nary tract and the virulence of the pathogenic organisms. A few common extensively studied 
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factors are listed below. Few studies have found strong correlation of increased predilection 
to development of UTI, whereas other researchers have not been able to prove the association.
2.1. Gender
Most of the studies show that incidence of UTI is more common in females as compared to 
male patients who undergo renal transplantation [12]. The mean distance from the urethra to 
anus is less in females as compared to males, which leads to increased susceptibility for vagi-
nal colonization with uropathogens [14, 26]. Menegueti et al. reported female sex as the only 
risk factor for post-transplant UTI [27]. Camargo et al. also reported a higher incidence of UTI 
in female patients [44.4%], despite higher prevalence of male patients in the study. However 
few studies do report a higher incidence of UTI in males. This could be due to the larger num-
ber of male patients receiving transplant in majority of the cohorts [8]. It is well documented 
that women with recurrent UTI have increased susceptibility to vaginal colonization with 
uropathogens. Sexual intercourse, using spermicidal products, maternal history of UTI and 
UTI at an early age predispose these patients to recurrent infections of the urogenital tract [1].
2.2. Catheterization and presence of ureteral stent
It has been observed that increased hospital stay and late removal of the catheter is an inde-
pendent risk factor for developing UTI [1]. Ostaszewaska et al. reported a strong correlation 
between occurrence of UTI and length of hospital stay [28]. Stamm et al. reported that the risk 
of UTI in renal allograft recipients is more by approximately 5% with each day of bladder cath-
eterization [29]. Dantass et al. also had similar observations [30]. Fayek et al. report a higher 
rate of UTI of 14.2% in transplant recipients with stents as compared to 7.9% without stent [31].
2.3. Anatomical abnormalities
Structural abnormalities of native or transplanted kidney predisposes to increased risk of 
developing UTI [1, 2]. The anatomical abnormalities could be vesicoureteral reflux, neuro-
genic bladder or presence of benign prostatic hyperplasia, are usually associated to increased 
risk for developing UTI [14, 28, 29].
2.4. Immunosuppressants
A wide variety of immunosuppressants are used in transplant medicine either as induction 
agents or for maintenance therapy. Recipients subjected to antimetabolite (azathioprine or 
mycophenolate mofetil) and induction therapy with cell depleting antibodies (antithymocyte 
globulin) are reported to have higher incidence of UTI [1, 32–34]. Prednisone dose of >20 mg/ 
day and multiple rejection therapies are associated with increased risk [35].
2.5. Deceased versus living donor transplants
It has been documented by various studies that the incidence of UTI is more in patients who 
receive kidney from deceased donor as compared to living donor. Taminato et al., reported 
that there is a greater risk for the patients who receive organ from deceased donor as against 
recipients of living donor with an odds ratio of 2.65 [36]. Similar observations were reported 
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by Ostaszewaska et al., R.Parasuraman et al., Camargo et al., Orhan Deniz Kara et al. and 
Abdulmalik MA et al. [2, 26, 28, 37, 38].
2.6. Human leucocyte antigen (HLA) match and rejection episodes
HLA compatibility and association with UTI was studied by Ostaszewaska et al. They 
observed that individuals with more than four HLA mismatches are more likely to develop 
UTI [28]. Patients who develop rejection episodes show increased incidence of UTI. These 
individuals are subjected to increased dosages of immunosuppression which may likely pre-
dispose these individuals to increased risk of developing UTI [9]. Moradi et al. evaluated the 
relationship between UTI and biopsy proven chronic rejection in a cohort of 100 patients over 
a period of 5 years. They concluded that patients with chronic rejection had more episodes of 
UTI as compared to those without rejection [39].
2.7. Other proposed factors
Apart from the important factors listed above, various other factors have been implicated 
in developing UTI. Older age has been related to an increased risk for UTI. The same study 
reported that an increase of 5 years in age at transplant increased the risk for UTI. Benign pros-
tatic hyperplasia and menopause, was an additional risk factor for developing UTI [26, 37, 38]. 
Delayed graft function (DGF), usually associated with deceased donor organ transplant has 
been documented as a risk factor for development of UTI [9]. Study reported that occur-
rence of DGF strongly correlates with the incidence of UTI, with 61.8% patients with UTI 
developing delayed graft function [28]. Other factors that have been implicated are presence 
of comorbid conditions like hypertension and diabetes, prolonged cold ischemia time, serum 
creatinine levels of >2 mg/dL and chronic viral infections [6, 14, 26–28, 35, 37, 39].
3. Etiology of UTI in renal transplant patients
3.1. Etiological agents
The most common type of UTI is bacterial followed by fungi and rarely viruses are implicated 
in pathogenesis of UTI. Gram negative bacteria are the most common pathogens cultured 
from the urine of renal transplant patients with UTI, followed by candida and viruses.
3.2. Bacteria
E. coli is the most common, accounting for more than 70% of the cases. Enterobacteriaceae, 
Enterococci, Pseudomonas and coagulase-negative staphylococci are other common agents. 
Mycobacterium tuberculosis, Salmonella and Mycoplasma are encountered rarely [2, 6, 38, 41, 
42]. A retrospective study by Espinar MJ et al., showed that renal allograft recipients are particu-
larly susceptible to infection by Enterobacteriaceae-producing extended-spectrum β-lactamases 
(ESBLs). Diabetes mellitus, previous antibiotic prophylaxis or therapy, previous UTI, relapsing 
infection and patients with delayed graft function after transplant represented risk factors for 
infection by ESBL positive Enterobacteriaceae. It was also observed that these patients present 
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early with UTI and exhibit higher resistance to fluoroquinolones, trimethoprim-sulfamethoxa-
zole and gentamicin. Pourmand MR et al. and Tawab et al. studied renal transplant recipients 
who developed recurrent UTI. E. coli was the most common cultured organism from the urine of 
patients with recurrent UTI. Coagulase negative staphylococci and Bacillus were rare [2, 9, 22].
3.3. Fungus
Candida is the most common cause for UTI in renal transplant recipients and is usually 
asymptomatic. Serious complications can occur following ascending infections. Fungal balls 
can be formed that may cause obstruction at the ureterovesical junction [2, 3, 43].
3.4. Viruses
The most common viruses that cause viral UTI in a renal transplant patient are cytomegalo-
virus and type 1 human polyomavirus (BKV). Clinically they present with fever, acute graft 
rejection, tubulointerstitial nephropathy and renal vascular disease. BKV-associated nephrop-
athy may be a frequent cause of recurrent post-transplant infections and these patients usu-
ally present as sterile pyuria, eosinophiluria and hematuria. Ureteral cell hyperplasia leading 
to ureteral obstruction has also been reported [2, 3, 40–43].
3.5. Schistosoma haematobium
Trematode involves the urinary tract and kidney, and the diagnosis is based on the visualization 
of parasite ova in urine specimens. The urine should be collected close to noon, when egg excre-
tion is maximal. Reactivation of a prior infection due to immunosuppression has been described 
in solid organ transplant recipients. Any solid organ transplant recipient from an endemic at risk-
area developing hematuria (with or without eosinophilia) should have urine examined to rule 
out the infection. S. haematobium should be treated with praziquantel both in the pre and post-
transplant period, as chronic infection can lead to squamous cell carcinoma of the bladder [44].
3.5.1. Causative organisms and identification of the organisms in our cases
Case 1:The microscopic examination of the urine sediment revealed plenty of pus cells with occasional 
red blood cells and bacilli. (Figure 1). Urine culture study was performed. On nutrient agar large, 
circular, low convex, grayish, white, moist, smooth and opaque colonies were observed. On MacConkey 
Agar media the colonies were circular, moist, smooth, and pink and found to be lactose fermenting. 
(Figure 1a) On Gram’s stain, pink gram negative rods were identified. (Figure 1b) The sample was 
further subjected to VITEK 2 system for identification and culture sensitivity. Escherichia coli was iden-
tified as the causative organism with sensitivity to Piperacillin/ Tazobactum, Sulbactum, Imipenem, 
Meropenem, Amikacin, Colistin, Levofloxacin and Minocycline. However resistance to Trimetoprim/ 
Sulfamethoxazole, Gentamycin and Cefepime was observed.
The patient was treated with intravenous administration of Cefoparazone-salbactam and Levofloxacin 
for 7 days. Urine routine and culture sensitivity studies were performed on sixth day. There was reduc-
tion in the total leucocyte count to 8.4 × 106/μl, with normal differential count. The serum creatinine 
level dropped from 2.4 to 1.8 mg/dL on seventh day. Urine routine microscopic examination revealed 
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scattered 15–20 WBC/ hpf. The patient was shifted to oral antibiotics for next 3 days. The immunosup-
pression regimen constituted of Tacrolimus, Prednisone and Mycophenolate sodium. No tapering of the 
drugs was done. Urine examination and culture studies were negative thereafter. The patient responded 
well to the treatment and is on regular follow-up. His present serum creatinine is 1.8 mg/dL, 4 months 
Figure 1. Urine microscopy stained with hematoxylin and eosin stain shows plenty of leucocytes and few bacilli. 
(Hematoxylin and eosin, x 400). (a) MacConkey agar media with circular, moist, smooth, and lactose fermenting pink 
colonies. The left upper quadrant is the patient sample and right upper quadrant depicts the positive control. (b) Gram’s 
stain, these bacilli appeared to be as pink gram negative rods (Gram’s stain, x 400).
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after the episode of urinary tract infection.Case 2:The microscopic examination of the urine sediment 
revealed clusters of pus cells, scattered epithelial cells and fungal buds and pseudohyphae. (Figure 2) 
Urine culture study was performed on Sabouraud’s dextrose agar. 65 g of the media was suspended in 
distilled water, mixed to form a uniform suspension, heated, boiled and then sterilized at 118–121°C for 
15 min. The urine sample was streaked using inoculating loop and incubated in 37°C for 48 hours. The 
growth appeared in 48 hours as cream/white colored, smooth and pasty colonies. (Figure 2a). A drop of 
inoculated broth media was placed onto the slide and a drop of lactophenol cotton blue stain was added 
and examined under the microscope which revealed the presence of chlamydospores. (Figure 2b).
The patient was treated with oral antifungal agent, fluconazole, 100 mg/day for 21 days along with con-
ventional Tacrolimus-based immunosuppressive regimen. Urine routine and culture sensitivity studies 
were performed on tenth day. There was reduction in the total leucocyte count to 6.35 x 10 6/μl, with nor-
mal differential count. The serum creatinine level dropped to 1.6 mg/dL. Urine examination and culture 
studies were negative thereafter. The patient responded well to the treatment and is on regular follow-up. 
Her present serum creatinine is 1.76 mg/dL, 4 months after the episode of urinary tract infection.
Figure 2. Hematoxylin and eosin stained urine deposit reveals budding fungi along with pseudohyphae. (a) Creamy and 
smooth colonies of candida on Sabouraud’s dextrose agar (red arrow). (b) Lactophenol cotton blue (wet preparation) 
reveals budding fungi (LCB, X 400)with chlamydospores (LCB, X 1000).
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4. UTI and effect on renal allograft function
4.1. Negative impact of urinary tract infections in renal transplant recipients
It has been well documented that development of UTI in renal transplant recipients is associ-
ated with increased rates of health resource utilization, which includes length of stay as well 
as more economic burden. Longer hospital stay exposes these individuals to increased risk of 
development of nosocomial infection [2, 8].
4.2. Effect on graft function
Mohan et al., in their prospective study of 31 patients who underwent renal transplantation, 
found that infections in the immediate post-transplant period adversely affected the graft 
survival. Mortality rate in patients with UTI was reported as 12.9% [9].
Abbott and colleagues undertook a retrospective cohort study of 28,942 Medicare primary 
renal transplant recipients in the U.S. Renal Data System database from 1996 through 2000, 
assessing Medicare claims for UTI occurring later than 6 months after transplantation based 
on ICD-9 codes, and found that the cumulative incidence of UTI during the first 6 months 
after renal transplantation was 17% (equivalent for both men and women) and at 3 years was 
60% for women and 47% for men (𝑃 < 0.001 in Cox regression analysis). Late UTI was signifi-
cantly associated with an increased risk of subsequent death and graft loss [45].
In a study by Dhamidharka et al., who analyzed US Renal Data System database over the 
period of 1996 to 2000 (up to 36 months post-transplant). 265 (30.5%) pediatric patients had 
either inpatient or outpatient claims for UTI out of total 870 pediatric patients who qualified 
for the study. The authors found that early UTI (less than 6 months after transplant) was 
significantly [𝑃  = 0.007 upon multivariable Cox regression] associated with higher adjusted 
hazard ratio of graft loss, and late UTI was not associated with such an outcome. Risk for 
post-transplantation death was not increased significantly after either early UTI (AHR 1.23; 
95% CI 0.37 to 4.08) or late UTI (relative risk 2.22; 95% CI 0.90 to 5.44) [46].
Pelle, et al. as well as Giral et al. reported that acute pyelonephritis of the graft is accom-
panied by renal failure and is an independent risk factor for impaired renal function as 
well as graft loss [47, 48]. Bodro et al. reported 1-year mortality rate of 3% in patients 
who developed worsening of graft function secondary to graft acute pyelonephritis. They 
further discovered that in patients with UTI due to a resistant strain of bacteria, the impair-
ment of graft function is more frequent than in patients who develop UTI due to non-
resistant strain bacteria [13]. Several hypotheses have been put forward to explain the 
negative impact of UTI on graft function. It has been postulated that bacterial infection 
activated the immune system, which can trigger the rejection cascades leading to acute or 
chronic rejections, causing deterioration of the graft function. Some authors propose that 
inflammation secondary to infection can cause scarring of the renal tissue, leading to loss 
of the functioning nephron mass causing impairment of renal function [49–51]. Reduction 
in the immunosuppressive agents following an episode of infection may accentuate the 
rejection process [13].
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Various studies like the one by Ostaszewska et al., have found out no significant difference 
related to UTI and graft survival [28]. Fiorante et al. also in their study of 189 renal allograft 
recipients, over a follow-up of 36 months, did not find an association between asymptom-
atic and symptomatic bacteriuria with graft dysfunction. They also did not report statis-
tically significant association between graft dysfunction and acute pyelonephritis of the 
graft [42]. Similarly, Ariza et al. and Lee et al. did not report any significant graft survival 
and UTI [52].
5. Management of UTI
Definitive diagnostic and treatment protocols for renal transplant patients are not well-defined. 
The current treatment protocols depend mainly on the severity of the infection, the local epi-
demiological data and the results of the culture reports. Complete urinalysis with microscopy 
along with culture studies is recommended. It has been proposed that bactericidal antibiotics 
should be preferred to bacteriostatic ones, which might be insufficient to cure the infection 
since the immune system cannot eradicate the dormant bacteria. Managing the predisposing 
factors is equally essential. The need for adequate immunosuppression and dose adjustment 
is also important. Various pharmacological interactions exist between antibiotics used to treat 
post-transplant UTI and immunosuppressant drugs. Ciprofloxacin and erythromycin are 
implicated in raising Calcineurin inhibitor (CNI) levels. Levofloxacin and ofloxacin usually 
do not interfere with CNI levels. Antifungal agents inhibit cytochrome P450 and increase CNI 
levels. Rifampin, imipenem and cephalosporin can reduce CNI levels. Nephrotoxic antibiotics 
(e.g., aminoglycosides, amphotericin) may have synergistic effects with CNIs, increasing renal 
damage.
UTI can co-exist with CMV, BKV and other viral and fungal diseases.
5.1. Management of asymptomatic bacteriuria
No definitive consensus or management is available for treatment of asymptomatic bacte-
riuria. However many of the researchers agree that there is no need to subject patients with 
asymptomatic bacteriuria to antibiotics as there are not enough studies that prove that 
asymptomatic bacteriuria heralds a negative outcome. Also studies have shown that treat-
ment of this entity does not prevent occurrence of significant bacteriuria in the later post-
transplant period [39]. Few studies have demonstrated that use of antimicrobials in patients 
with asymptomatic bacteriuria is usually unsuccessful in removing the offending agent; also 
it does not prevent the occurrence of subsequent UTI [53]. Study by Goya et al. proposed 
that considering asymptomatic bacteriuria as a precursor for symptomatic bacteriuria and 
subsequent development of pyelonephritis and high risk of developing symptomatic UTI in 
early transplant period that may affect the graft function it is recommended to keep patients 
with asymptomatic bacteriuria under screening schedules. Treatment with narrow-spectrum 
antibiotics of short duration of 5–7 days following culture report is recommended [54].
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5.2. Symptomatic UTI
Symptomatic bacteriuria is classified further as mild, moderate and severe. Any predisposing 
conditions have to be treated. For mild cases empirical therapy with oral antibiotics, prefer-
ably ciprofloxacin with or without amoxicillin for a period of 5–7 days is recommended. For 
moderate infections, treatment with ciprofloxacin or ceftriaxone or ampicillin-salbactum is 
advised for 14 days after the culture sensitivity reports are obtained. For severe symptom-
atic UTI empirical treatment with pipercillin-tazobactum or cefepime is recommended over 
a period of 14–21 days following culture sensitivity report. Multi-drug resistant organisms 
need to be kept in mind before starting the empirical therapy. Carbapenem is the drug of 
choice for such cases. For recurrent UTI the treatment is extended to 6 weeks.
5.3. Candiduria
In patients with asymptomatic candiduria, there is no recommended treatment. In cases of 
symptomatic candiduria fluconazole, 200–400 mg, orally per day for 14 days is the treat-
ment of choice. Fluconazole may have drug interactions with Calcineurin inhibitor, hence 
dose adjustment is recommended. Disseminated cases would require treatment by intra-
venous amphotericin B, 0.3–1 mg/kg/day for 1–7 days. Flucytosine [25 mg/kg every 6 h 
for 7–10 days] can also be used, but with caution, especially in cases of renal dysfunction. 
Monitoring for cytopenias, rash, gastrointestinal symptoms and hepatotoxicity is recom-
mended [55, 56].
6. Prevention
Although the data from various studies does not provide a concrete evidence for post-
transplant UTI to have a profound effect on graft dysfunction, but overall it is necessary 
to control infection related mortality. It is quite obvious from certain studies that UTI or 
any infection leads to increase in duration of stay at hospital as well as it adds to economic 
burden as discussed in this review. Infection of any sort can have a psychological effect on 
the transplant recipient too. With advent of wide range of antimicrobials available as well as 
vast advancement in the field of transplantation medicine, losing graft function to infections 
should not be acceptable. Hence it is important to identify the various risk factors and employ 
strategies to prevent the development of infections in these subset of patients. Individuals 
with high risk factors like those having structural anomalies of the urinary tract, old age 
patients, females, presence of comorbid conditions like diabetes, hypertension should be kept 
under proper surveillance. In case of living donors a thorough screening for infections before 
transplantation though serological tests, urine analysis and hematology is advisable to rule 
out possibility of any infections.
Certain studies have emphasized the role of antimicrobial prophylaxis with trimethoprim-
sulfamethoxazole (TMP-SMZ) for prevention of UTI. TMP-SMZ is a broad spectrum 
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antimicrobial agent, with relatively low cost and is mostly used for prevention of Pneumocystis 
carinii infection [2, 14, 51]. Ariza-Heredia et al. have reported the effect of TMP-SMZ pro-
phylaxis offers great protection to prevent UTI in the first year. Four patients who were not 
offered this prophylaxis due to certain reasons developed UTI in first year of transplant as 
against those who received the prophylaxis [14].
In cases with recurrent UTI anatomical and functional abnormalities like vesicoureteral reflux 
and neurogenic bladder need to be addressed and managed accordingly. The patients should 
be educated for basic preventive measures like hydration and frequent voiding. Radiological 
studies should be implicated to rule out the anatomical defects, obstruction, calculi and 
retained foreign bodies. Prostatitis should be considered as an important differential diag-
nosis in men who present with recurrent post-transplant UTI. Mitra et al. have proposed a 
scheme for evaluating a case of recurrent UTI (Figure 3) [57].
7. Recommendations
As the risk of UTI is very high in the first week of transplantation, we recommend that every 
renal transplant recipient should undergo urine routine examination with microscopy for 
first 10 days in the post-operative period irrespective of the fact that the patient has any 
Figure 3. Scheme for evaluating a case of recurrent UTI.
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symptoms of UTI. This type of screening will be helpful in early diagnosis and treatment 
and preventing infection related mortality. Culture studies should be advised as and when 
required, and the treatment should be planned according to the organisms identified in the 
culture studies. Antibiotic prophylaxis should be given to patients who are at high risk for 
developing UTI. Urine examination should be advised during every follow-up. This practice 
will definitely help in early diagnosis of infection and help in preventing morbidity associated 
with UTI.
8. Conclusion
Urinary tract infections in the post-transplant period are quite common, more so during 
the early period of first 3 months. There are various risk factors attributed to development 
of UTI like female sex, delayed graft function, old age, anatomical anomalies and organs 
from the deceased donors being more common. Although few studies have identified UTI 
in post-transplant period as a negative predictor for graft function, further studies are still 
required to establish this relationship. The criteria to define asymptomatic bacteriuria and 
UTI are the same as that for general population. However in view of studies that show that 
post-transplant UTI has deleterious effect on graft function, it is necessary to design standard 
definitions, protocols for surveillance, prevention and management of UTI in renal transplant 
recipients.
However our protocol for renal transplant recipients involves regular follow-up by urine rou-
tine and microscopic examination and renal function tests, which helps in early detection of 
infections leading to prompt management. Thus, early intervention in both the patients led to 
restoration of the renal function with proper graft function.
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